DEXOLIGO
Live / Registered — Registered (as of 14 Jan 2025)
What this means for you
Registered since 14 Jan 2025. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79384444
- Registration number
- 7646613
- Mark type
- Stylized text
- Filed
- 02 Aug 2023
- Published for opposition
- 26 Nov 2024
- Registered
- 14 Jan 2025
- Attorney of record
- Sebastian Lovera, esq.
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations, namely, oligonucleotides, siRNA and antisense RNA for use in the treatment of cancer, hepatitis, neurodegenerative diseases, neurological diseases, hemophilia, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, rare bleeding disorders, iron overload disorders, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, chronic liver infection, anemia, myeloproliferative disorders, auto-immune disorders, chronic kidney diseases, obesity, type 2 diabetes, metabolic syndrome and related conditions, thrombocythemia, gout
Owner
Prosecution history
- 15 Aug 2025 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 25 Jul 2025 — FINAL DISPOSITION NOTICE SENT TO IB
- 24 Jul 2025 — FINAL DISPOSITION PROCESSED
- 24 May 2025 — NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
- 06 May 2025 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
- 06 May 2025 — NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
- 15 Apr 2025 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 14 Jan 2025 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 14 Jan 2025 — REGISTERED-PRINCIPAL REGISTER
- 26 Nov 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 26 Nov 2024 — PUBLISHED FOR OPPOSITION
- 20 Nov 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 31 Oct 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 16 Oct 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 15 Oct 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE